Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma

• Published in: Journal of personalized medicine Vol. 13; no. 4; p. 666
• Main Authors: Geng, Chuanying, Yang, Guangzhong, Zhou, Huixing, Wang, Huijuan, Li, Yanchen, Leng, Yun, Zhang, Zhiyao, Jian, Yuan, Chen, Wenming
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 14.04.2023; MDPI
• Subjects: Age; Brain natriuretic peptide; Calcium (blood); Creatinine; Cytogenetics; Dehydrogenases; Disease; Hemoglobin; Hospitals; Induction therapy; L-Lactate dehydrogenase; Medical prognosis; Medical research; Medicine, Experimental; Multiple myeloma; Multivariate analysis; Natriuretic peptides; Patients; Precision medicine; Regression analysis; Remission (Medicine); Risk factors; Risk groups; Beijing China; China; multiple myeloma; ultra-high-risk; prognosis; survival
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm13040666

To investigate the clinical characteristics and risk factors of ultra-high-risk (UHR) patients with newly diagnosed multiple myeloma (MM). We screened UHR patients with a survival of less than 24 months and we selected patients with a concurrent survival of more than 24 months as a control group. We retrospectively analyzed the clinical characteristics of UHR patients with newly diagnosed MM and screened related risk factors. In total we analyzed 477 patients, which included 121 (25.4%) UHR patients and 356 (74.6%) control patients. Median overall survival (OS) and progression-free survival (PFS) of UHR patients was 10.5 months (7.5-13.5 months) and 6.3 months (5.4-7.2 months), respectively. Univariate logistic regression analysis showed that age > 65 years, hemoglobin (HGB) < 100 g/L, lactate dehydrogenase (LDH) > 250 U/L, serum creatinine (SCr) > 2 mg/dL, corrected serum calcium (CsCa) > 2.75 mmol/L, B-type natriuretic peptide (BNP) or N-terminal prohormone BNP (NT-proBNP) > 2 upper limit of normal (ULN), high-risk cytogenetics, Barthel index score, and International Staging System (ISS) stage III were associated with UHR MM. In a multivariate analysis, age > 65 years, LDH > 250 U/L, CsCa > 2.75 mmol/L, BNP or NT-proBNP > 2 ULN, high-risk cytogenetics, and Barthel index score were independent risk factors for UHR MM. Moreover, UHR patients had a worse response rate than control patients. Our study highlighted the characteristics of UHR MM patients and suggested that the combination of organ insufficiency and highly malignant myeloma cells resulted in poor outcomes of patients with UHR MM.